期刊文献+

Toll样受体信号通路在调控树突状细胞成熟中的作用研究 被引量:2

Study on the effect of Toll like receptor signaling pathway on the regulation of dendritic cell maturation
下载PDF
导出
摘要 目的探讨TLR信号通路在调控树突状细胞(DC)熟过程中的作用。方法用密度梯度离心法从人外周富集血中分离单个核细胞(PBMC),以GM-CSF和IL-4体外诱导成未成熟DC(imDC),用电穿孔法把A549的总RNA转染入imDC,分别用传统细胞因子鸡尾酒(IL-1β、IL-6、TNF-α、PGE2)和改良细胞因子鸡尾酒(IL-1β、IL-6、TNF-α、PGE2、polyⅠ∶C、CpG ODN)刺激DC的成熟。实验分为4组,对照组:GM-CSF、IL-4;传统组:传统细胞因子鸡尾酒;改良1组:IL-1β、IL-6、TNF-α、polyⅠ∶C、CpG ODN);改良2组:IL-1β、IL-6、TNF-α、PGE2、polyⅠ∶C、CpG ODN。用RTPCR法检测RNA的转染效率,流式细胞术检测DC和DC致敏T细胞的表面标志,ELISA法检测IL-12的分泌水平,MTT法检测T细胞的增殖。结果 1)RT-PCR检测:电穿孔法能使A549的总RNA成功转入DC,并使DC表达组织多肽特异性抗原(TPS)、癌胚抗原(CEA)和细胞角蛋白19片段(Cyfra21-1)等肿瘤抗原。2)流式检测:CD83各组表达率分别为(15.17±1.61)%、(64.33±7.58)%、(60.26±4.18)%和(82.89±3.06)%,CD1a表达率分别为(25.74±6.06)%、(69.37±8.16)%、(61.66±5.82)%和(86.07±5.63)%(P<0.05),各组CD8+T细胞比例分别为(36.43±3.15)%、(61.91±2.33)%、(54.81±2.55)%和(66.78±2.74)%(P<0.05)。3)各组IL-12的分泌水平分别为(55.86±14.07)、(1 243.49±57.57)、(744±49.51)和(2 385±128.98)pg/mL(P<0.05)。4)各组刺激指数分别为11.85±2.61、54.14±3.81、47.57±3.14和64.43±5.88,阳性对照组为135.29±5.06(P<0.05)。结论TLR配体polyⅠ∶C和CpG ODN可以促进DC的分化成熟。 Objective To explore the effect of TLR signaling pathway in the process of DC maturation. Methods Peripheral blood mononuclear cells (PBMC) were isolated using density gradient centrifugation. Immature dendritic cells (imDC ) were induced by GM-CSF and IL-4 in vitro and were transfected with the total RNA extracted from A549 cells into imDC using electroporation. And then the imDC with A549-RNA transfacted were stimulated with traditional cocktail of cytokines ( IL- 1β, IL-6, TNF-α, PGE2 ) and modified cocktail of cytokines ( IL-1β, IL-6, TNF-α, PGE2, poly I : C, CpG ODN ), respectively. The experiments were divided into four groups, control group:GM-CSF, IL-4;traditional group:traditional cocktail of cytokines ; modified group 1 : IL-1β, IL-6, TNF-α, poly I : C, CpG ODN ; modified group 2 : IL-1β, IL-6, TNF-α, PGE2, poly I : C, CpG ODN. RNA transfection efficiency was detected by RT-PCR, surface markers of the DC and DC sensitized T cell were detected by flow cytometry,T cell proliferation was judged by MTY, the secretion of IL-12 were detected by ELISA. Results 1 )RT-PCR showed that the A549-RNA were transfected into the DC successfully by the method of electroporation, and these DC could express three tumor antigens, including tissue polypeptide specific antigen (TPS), carcino-embryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra21-1). 2) Flow showed that CD83 expression rates in the above groups were (15.17 ±1.61) % ,(64. 33 ±7.58)% ,(60.26 ±4.18)% and (82.89±3.06)% ,CDla expression rates were (25.74± 6.06)% ,(69.37 ±8.16)% ,(61.66 ±5.82)% and (86.07 ±5.63)% ,the proportion of CD8^+T cells were (36.43 ±3. 15)% ,(61.91 ±2.33)% ,(54.81 ±2.55)% and (66.78 ±2.74)% ,all these differenees were statistically significant (P 〈 0.05 ). 3 ) The secretion of IL- 12 in the above groups were (55.86 ±14.07 ) pg/mL, ( 1 243.49 ±57.57 ) pg/mL, (744±49.51 ) pg/ml and ( 2 385 ±128.98 ) pg/mL(P 〈 0. 05 ). 4 ) Stimulation index in the above four groups and positive control group were 11.85 ± 2.61,54.14 ± 3.81,47.57 ± 3.14,64.43 ±5.88 and 135.29 ±5.06 (P 〈 0. 05 ). Conclusion TLR ligand poly I : C and CpG ODN can optimize the maturation of DC.
出处 《中国输血杂志》 CAS CSCD 北大核心 2014年第5期473-479,共7页 Chinese Journal of Blood Transfusion
基金 国家自然科学基金面上项目(81172172)
关键词 树突状细胞 细胞因子鸡尾酒法 改良 成熟诱导 A549-RNA 电转染 RT—PCR TLR配体 poly I C CPG ODN dendritic cell cocktail of cytokines modified maturation induction A549-RNA electroporation reverse transcriptase polymerase chain reaction toll-like receptor ligand poly I : C CpG ODN
  • 相关文献

参考文献28

  • 1祁慧薇,范理宏.PI3K/Akt/mTOR信号转导通路与非小细胞肺癌[J].中国肺癌杂志,2010,13(12):1149-1154. 被引量:21
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin,2013,62 ( 1 ) : 11-30.
  • 3Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first .FDA-approved therapeutic cancer vaccine. Clin Cancer Res,2011,17 ( 11 ) :3520-3526.
  • 4Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendriticc cell vaccination combined with CTLA4 blockade in patients with meta- static melanoma. Clin Cancer Res ,2009,15 ( 19 ) :6267-6276.
  • 5Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell based vaccination of patients with malignant melanoma:assessment of correlation between clinical re- sponse and vaccine parameters. Cancer lmmunol Immunotherg, 2009,58 ( 1 ) : 1-14.
  • 6Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intraeellular regulators of infection and inflammation. Nat Rev Im- munol,2007,7( 1 ) :31-40.
  • 7Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polari- zing program in dendritic cells. Nat Immunol, 2005,6 ( 8 ) : 769- 776.
  • 8Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen presentation. Nat Immunol, 2006,7 ( 10 ) : 1029 -1035.
  • 9Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunosti mulatory dendritic cells under fetal calf serumfree conditions. Eur J Immu- nol, 1997,27(12) :3135-3142.
  • 10Sokolova V, Knusehke T, Kovtun A, et al. The use of calcium phos- phate nanopartic'les encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomateriais ,2010,31 (21) :5627-5633.

二级参考文献25

  • 1张超,杨娜,章雄文,丁健.靶向PI3K-Akt-mTOR信号通路抑制剂的研究进展[J].中国癌症杂志,2006,16(12):1064-1070. 被引量:22
  • 2ZHANG Yu-hua,WEI Wei,XU Hao,WANG Yan-yan,WU Wen-xi.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways[J].Chinese Medical Journal,2007(9):743-748. 被引量:13
  • 3Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med, 1996, 154(3 Pt 1): 725-733.
  • 4Wojcik E, Kulpa JK, Sas-Korczyfiska B, et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res, 2008, 28(5B): 3027-3033.
  • 5Nisman B, Amir G, Lafair J, et a l. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res, 1999, 19(4C): 3549-3552.
  • 6Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in non-small cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer, 1998, 82(10): 1850-1859.
  • 7Benwell RK,Lee DR.Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendriticcells.Clin Immunol,2010,134(2):178-187.
  • 8Burchell JT,Strickland DH,Stumbles PA.The role of dendritic cells and regulatory T cells in the regulation of allergic asthma.Pharmacol Ther,2010,125(1):1-10.
  • 9Fukuiwa T,Sekine S,Kobayashi R,et al.A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells forprolonged mucosal immunity.Vaccine,2008,26(37):4849-4859.
  • 10Capitini CM,Mackall CL,Wayne AS.Immune-based therapeutics for pediatric cancer.Expert Opin Biol Ther,2010,10(2):163-178.

共引文献46

同被引文献28

  • 1朱春森,徐春厚.酵母细胞壁多糖的研究进展[J].饲料与畜牧(新饲料),2007(9):29-31. 被引量:9
  • 2Boudreau JE, Bonehill A, Thielemans K, et al. Engineering den- dritic cells to enhance cancer immunotherapy. Mol Ther, 2011, 19 (5) :841-853.
  • 3Zitvogel L, Apetoh L, GhiringheIIi F, et al. The anticancer im- mune response: indispensable for therapeutic success? J CIin In- vest 2008, 118 (6) : 1991-2001.
  • 4Hjek R, Butch AW. Dendritic cell hiolo and the application of dendritic cells to immunotherapy of multiple myeloma. Meal Once|, 2000, 17(I ) :2-15.
  • 5Jonuleit H, KUhn U, MflIIer G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic ceils under fetaIcalf serum-frce conditions. Eur J Immu- nol, 1997, 27(12) :3135-3142.
  • 6Pedersen AE, Thorn M, Gad M, et al. Phenotypic and functional characterization of clinical grade dendritic ceils generated from pa- tients with advanced breast cancer for therapeutic vaccination. Scand J Immunol, 2005, 61 (2) :147-156.
  • 7Lesterhuis WJ, Aarntzen EH, De Vries U, et al. Dendritic cell vaccines in melanoma: from promise to proof ? Crit Rev Oncol He- matol, 2008, 66(2) :118-134.
  • 8Skalova K, Mollova K, Michalck J. Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine, 2010, 28 (32) : 5153-5160.
  • 9Schreibeh G, Benitez-Ribas D, Schuurhuis D, et al. Commonly used prophylactic vaccines as an alternative for synthetically pro- duced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010, 116(4) :564-574.
  • 10Jangmans W, Tiemessen DM, van Vlodrop U, et al. Thl-polari- zing capacity of clinical-grade dendritic cells is triggered by Ribo- muny but is compromised by PGE2: the importance of maturation cocktails. J Immunother, 2005, 28 (5) :480-487.

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部